Insulet reports Q3 adjusted EPS $1.24, consensus $1.15

Reports Q3 revenue $706.3M, consensus $679.01M. “We delivered strong third quarter results, a testament to our team’s exceptional performance and the transformative power of Omnipod 5 for people living with diabetes,” said Ashley McEvoy, CEO. “Our continued meaningful engagement with physicians, partners, investors, and our incredible Podder community further reinforces our unique role at the nexus of consumer health, healthcare, and medtech. We’re not just advancing diabetes care-we’re reshaping it. As we continue to grow, I’m energized by our potential to expand access, accelerate growth, and deliver lasting value for all our stakeholders.”